Alignment Healthcare, Inc. (NASDAQ:ALHC) Insider Sells $270,444.00 in Stock

Key Points

• Hyong Kim sold 18,600 shares of Alignment Healthcare at an average price of $14.54, totaling approximately $270,444, and now owns 490,767 shares valued at over $7 million, representing a 3.65% decrease in his position.
• Alignment Healthcare reported a quarterly revenue of $1.02 billion, exceeding estimates of $960.25 million and showing a 49% increase from the same quarter last year.
• Analyst ratings vary, with a consensus of "Moderate Buy" and an average target price of $18.56, reflecting mixed confidence in the stock’s performance.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Hyong Kim sold 18,600 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $14.54, for a total value of $270,444.00. Following the sale, the insider owned 490,767 shares in the company, valued at $7,135,752.18. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Alignment Healthcare Stock Performance

NASDAQ ALHC traded up $0.60 on Monday, hitting $15.65. 528,672 shares of the stock traded hands, compared to its average volume of 3,008,044. The business's fifty day moving average is $13.73 and its two-hundred day moving average is $15.30. Alignment Healthcare, Inc. has a 12 month low of $8.24 and a 12 month high of $21.06. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of -55.91 and a beta of 1.16. The company has a debt-to-equity ratio of 2.29, a quick ratio of 1.66 and a current ratio of 1.66.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.14. Alignment Healthcare had a negative return on equity of 43.68% and a negative net margin of 1.53%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $960.25 million. During the same quarter last year, the business posted ($0.13) earnings per share. The firm's revenue was up 49.0% compared to the same quarter last year. As a group, equities analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Institutional Trading of Alignment Healthcare

Several large investors have recently modified their holdings of the business. Alliancebernstein L.P. lifted its holdings in Alignment Healthcare by 2.8% in the fourth quarter. Alliancebernstein L.P. now owns 119,440 shares of the company's stock worth $1,344,000 after buying an additional 3,300 shares during the period. Franklin Resources Inc. purchased a new stake in Alignment Healthcare in the fourth quarter worth about $732,000. Wells Fargo & Company MN lifted its holdings in shares of Alignment Healthcare by 58.3% during the fourth quarter. Wells Fargo & Company MN now owns 48,813 shares of the company's stock valued at $549,000 after purchasing an additional 17,985 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Alignment Healthcare during the fourth quarter valued at approximately $1,769,000. Finally, Barclays PLC lifted its holdings in shares of Alignment Healthcare by 3.7% during the fourth quarter. Barclays PLC now owns 200,564 shares of the company's stock valued at $2,256,000 after purchasing an additional 7,118 shares during the last quarter. 86.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ALHC. Stephens raised Alignment Healthcare to a "strong-buy" rating in a research note on Monday, June 2nd. Barclays upgraded Alignment Healthcare from an "underweight" rating to an "equal weight" rating and increased their price objective for the stock from $9.00 to $13.00 in a report on Thursday, July 31st. Zacks Research raised Alignment Healthcare to a "hold" rating in a research report on Friday, August 8th. Wall Street Zen cut Alignment Healthcare from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Finally, UBS Group lifted their target price on Alignment Healthcare from $16.00 to $17.00 and gave the stock a "neutral" rating in a research note on Friday, May 2nd. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.56.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.